Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections
- 1 April 2007
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Anti-infective Therapy
- Vol. 5 (2), 177-184
- https://doi.org/10.1586/14787210.5.2.177
Abstract
Antimicrobial resistance among Gram-positive organisms continues to increase and has reached epidemic proportions in a number of countries and within medical centers worldwide. Daptomycin is a new lipopeptide antibiotic with rapid bactericidal activity against Staphylococcus aureus. It is also active against coagulase-negative staphylococci, enterococci and streptococci. It exerts its effect through cell membrane disruption that results in dissipation of the membrane potential. Daptomycin exhibits a prolonged postantibiotic effect and is well tolerated. In Phase III clinical trials, daptomycin was found to be similar in efficacy to standard therapy in complicated skin and skin structure infections. More recently, it was approved for the treatment of S. aureus bacteremia and right-sided endocarditis. Daptomycin is not indicated for pulmonary infections. Preliminary data suggest that daptomycin may be effective in urinary tract, bone and joint infections. However, randomized clinical trials are needed to confirm these findings. Daptomycin is an effective antimicrobial agent for the treatment of various serious Gram-positive infections, especially those caused by methicillin-resistant S. aureus.Keywords
This publication has 61 references indexed in Scilit:
- Comparative Bactericidal Activities of Daptomycin and Vancomycin against Glycopeptide-Intermediate Staphylococcus aureus (GISA) and Heterogeneous GISA IsolatesAntimicrobial Agents and Chemotherapy, 2006
- In Vitro Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus , Including Heterogeneously Glycopeptide-Resistant StrainsAntimicrobial Agents and Chemotherapy, 2006
- Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused byStaphylococcus aureusNew England Journal of Medicine, 2006
- Clinical Experience With Daptomycin in Patients With Orthopedic-Related InfectionsInfectious Diseases in Clinical Practice, 2006
- Induction of Daptomycin Heterogeneous Susceptibility in Staphylococcus aureus by Exposure to VancomycinAntimicrobial Agents and Chemotherapy, 2006
- Daptomycin-Resistant Enterococcus faecium in a Patient With Acute Myeloid LeukemiaMayo Clinic Proceedings, 2005
- Daptomycin‐Resistant, Methicillin‐ResistantStaphylococcus aureusBacteremiaClinical Infectious Diseases, 2005
- Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infectionsJournal of Antimicrobial Chemotherapy, 2005
- Postantibiotic Effects of Daptomycin against 14 Staphylococcal and Pneumococcal Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2003
- Resistance Studies with DaptomycinAntimicrobial Agents and Chemotherapy, 2001